Study Objectives: To investigate the therapeutic effect of dimethyl fumarate (DMF, an immunomodulatory agent) on obstructive sleep apnea (OSA), and potential influence of any such effect by selected proinflammatory molecules.
Introduction
Obstructive sleep apnea (OSA) is a common disorder characterized by repeated episodes of upper airway obstruction and hypoxia during sleep. This condition is estimated to affect 10%-20% of Americans and is a well-recognized risk factor for many serious consequences including hypertension, stroke, heart disease, diabetes, sleep-related motor vehicle accidents, and absenteeism in the workplace [1] [2] [3] [4] [5] [6] [7] . Taken together, costs associated with these consequences amount to billions of dollars each year.
Despite the profound public health and societal impact of OSA, many patients would rather suffer the consequences of this condition than utilize existing treatments. The first-line treatment for OSA, positive airway pressure (PAP), is delivered by a mechanical device and mask interface that act by splinting the upper airway open during sleep. Although PAP controls OSA, up to 50 per cent of patients cannot maintain adequate PAP adherence due to mask discomfort or pressure intolerance [7] . Although a minority of patients receive mechanical or surgical alternatives to PAP [8] , a safe, convenient medication would be favored in many cases. Pharmacological treatments have long been sought [9, 10] , but discovery of effective strategies has been hindered by incomplete understanding of the pathophysiology that underlies OSA.
Associations between inflammation and OSA are well established. Inflammation due to intermittent hypoxia is a recognized downstream consequence of OSA [11, 12] . Conversely, local or systemic inflammation may contribute to OSA severity [13] . Furthermore, proinflammatory cytokines, and molecules that promote immune cell trafficking, are elevated in the serum of individuals with OSA [14] [15] [16] [17] . The production of these molecules is thought to be driven, in part, by activation of the transcription factor, nuclear factor κ-B (NFκB) [18] . Previous studies have shown an association between treatment with immunomodulatory or immunosuppressive agents and reduced OSA severity or reduced OSA frequency [13, 19, 20] . Although these studies endorse inflammatory molecules as candidate therapeutic targets in OSA, dedicated trials that evaluate the effects of specific immunomodulatory agents on OSA severity are lacking.
Dimethyl fumarate (DMF), a fumaric acid ester, suppresses the production of proinflammatory molecules, including those that have been implicated in the pathogenesis of OSA [21, 22] . Fumaric acid esters are used for the treatment of psoriasis [23, 24] and have a history of off-label use for other inflammatory conditions, such as cutaneous and pulmonary sarcoidosis [25] [26] [27] . The FDA-approved formulation, Tecfidera (Biogen MA Inc.), is an oral, commercially available treatment for relapsing multiple sclerosis (MS), an autoimmune disease of the central nervous system [28] [29] [30] . We previously found that patients with MS treated with disease-modifying therapies have substantially less severe apnea than patients with MS not on such therapy [20] . Given its mechanism of action, oral administration, and favorable safety profile, DMF is a reasonable candidate for prospective immunomodulatory treatment of OSA.
The objective of this randomized, subject and rater-blinded, placebo-controlled trial was to determine the effects of DMF on OSA severity. We also sought to evaluate relationships, before and after DMF therapy, between apnea severity, plasma levels of proinflammatory cytokines and chemokines, and expression of NF-κB signaling molecules in peripheral blood mononuclear cells (PBMC). We hypothesized that at 4 months DMF would reduce both OSA severity and expression of proinflammatory molecules. We predicted that reduction in systemic levels of proinflammatory molecules might influence DMF treatment effect.
Methods

Standard protocol approvals, registrations, and patient consents
This study was conducted in accordance with good clinical practice. Study procedures were approved by the University of Michigan Institutional Review Board. The study was registered with ClinicalTrials.gov (NCT02438137). Written informed consent was obtained from all participants. Adverse events were captured and categorized using the Common Terminology Criteria for Adverse Events Version 4.0 (https://evs.nci.nih.gov/ ftp1/CTCAE/About.html).
Participants
Eligible participants of age 18-65 were recruited from July 2015 to December 2015. Eligibility criteria included the following: (1) Diagnosis of OSA, as confirmed by previous clinical sleep study (in-lab polysomnography, PSG); (2) Refusal, inability, or high reluctance to use PAP regularly (continuous, bilevel, or automatically adjusting PAP) for treatment of OSA, despite medical advice; (3) Willingness to undergo repeat sleep study and blood studies; (4) Presence of complete blood count (CBC) that included absolute lymphocyte count of ≥1.2 K/μL at screening.
Exclusion criteria included the following: (1) Regular use of PAP within the last 2 months; (2) Physical, psychiatric, or cognitive impairment that could prevent informed consent, PSG, or reliable follow-up; (3) Cardiac conditions (e.g. congestive heart failure or recent myocardial infarction); (4) Current successful treatment for obstructive or central sleep apnea; (5) History of surgical treatment for OSA within past 6 months, or subsequent to last PSG that confirmed presence of OSA; (6) Active nervous system diseases; (7) Systemic autoimmune disease such as rheumatoid arthritis or lupus; (8) Pregnancy or breastfeeding; (9) Use of immunotherapies or immunosuppressants, currently or within past 6 months; (10) Anticipated initiation or dose change in tricyclic antidepressants, selective serotonin uptake inhibitors, or related compounds; (11) History of active, serious, or persistent infections; (12) Recent surgery (within 3 months prior to screening), or anticipated surgery during the length of the study; (13) Systemic steroid use within the last 2 months (excluding local steroid injections or intranasal steroid spray); (14) Current diagnosis of cancer that was not considered to be cured or in remission by the treating physician, cancer treatment of any kind within the last 6 months prior to screening (chemo, radiation, surgery), or anticipated cancer treatment during the length of the study; (15) History of a lymphoproliferative disorder (such as leukemia); (16) History of multiple myeloma; (17) Lymphocyte count less than 1.2 K/μL at screening; (18) Refusal to use at least one reliable method of birth control (for women of childbearing age); (19) Newly diagnosed (within 2 months) OSA with AHI > 30 and history of serious, recent, or unstable cardiovascular disease; and (20) Report of previous motor vehicle accidents or near-misses presumed to be due to excessive sleepiness while driving.
Study protocol
A screening/baseline visit was performed to confirm eligibility, obtain consent, and collect baseline blood samples. Participants then underwent in-laboratory baseline PSG and were randomized in a 2:1 ratio (stratified by OSA severity, defined by an apnea-hypopnea index ≥ or < 30 events per hour) to receive DMF or placebo for 4 months. Participants who had a recent in-laboratory PSG for clinical purposes, at the University of Michigan and using the same procedures, within 2 months prior to enrollment, were allowed to waive their baseline PSG and were randomized to treatment on the day of their baseline visit.
Following randomization, participants were prescribed 120 mg capsules of DMF or placebo, in blisterpack wallets. All product was shipped directly from the manufacturer (Biogen MA Inc.) to the study site. To preserve blinding, DMF and placebo capsules were identical in appearance and capsule composition. Consistent with Tecfidera labeling for the treatment of MS, participants were instructed to take 120 mg twice a day for 1 week and then increase to a goal dose of 240 mg twice a day (480 mg daily). Participants on full dose who reported intolerable side effects that could threaten study continuation were offered slower dose escalations, or if necessary allowed to continue in the study at a reduced dose (120-360 mg daily). Total drug adherence was calculated as the total number of pills taken by the participant over the treatment interval, divided by the number of pills expected to be taken assuming a standard dose of 240 mg twice a day for that treatment interval. Five participants did not return their used blisterpacks at the conclusion of their study participation. For these participants, participant self-report was used to estimate drug adherence. All participants were allowed to continue medications that had been previously prescribed to them by their treating physicians, as part of routine clinical care.
Monthly follow-up visits that included repeat assessments of medical history, medication changes, adverse events, and drug reconciliation were conducted for 4 months. CBC with differential was repeated at months 2 and 4 postrandomization to monitor lymphocyte counts. Repeat in-laboratory PSG was performed following the month 4 follow-up visit. Participants also received a month 5 follow-up phone call to reassess and complete adverse event assessments, and to coordinate future sleep clinic visits for OSA care.
Polysomnography
Polysomnographic procedures and scoring followed the latest American Academy of Sleep Medicine Scoring Rules (version 2.2.0) [31] . Standard measures included the following: total sleep time (TST), sleep efficiency (SE; total sleep time multiplied by 100 and divided by total recording time), sleep latency (SL; minutes from lights out to first 30 s epoch of any sleep stage), wake after sleep onset (WASO; total time spent awake after sleep onset, and before final awakening time), total arousal index (TAI, average number of EEG arousals per hour of sleep), % total sleep time spent in stage N1, N2, N3, and R sleep, the respiratory disturbance index (RDI; total number of apneas, hypopneas, and respiratory-related arousals per hour of sleep), minimum oxygen saturation (MinO2), percentage of sleep time with O2 saturation ≤ 88 per cent, periodic leg movement index (PLMI; number of periodic leg movements per hour of sleep), and the periodic leg movement arousal index (PLMAI; number of periodic leg movements associated with arousals per hour of sleep). All PSGs were scored by an experienced, registered polysomnographic technologist, and reviewed by a board-certified sleep physician. Both were blinded to treatment allocation.
Immunological assays
PBMCs were isolated from participants using CPT Vacutainer tubes per manufacturer's protocol (BD, Fisher Scientific, Pittsburgh, PA). PBMCs were suspended in fetal bovine serum with 10 per cent dimethyl sulfoxide (DMSO) and stored in liquid nitrogen until thawed for NFκB analyses. Plasma was stored at −80°C until thawed for Luminex assays.
Multiplex bead-based cytokine analysis
Plasma levels of cytokines and chemokines were measured using Luminex 200 customized multiplex magnetic bead-based arrays (EMD Millipore, Billerica, MA), following the manufacturer's protocol. Standards were run in parallel to allow quantification of individual factors. The data described reflect levels that fell within the linear portion of the corresponding standard curve. Technicians performing Luminex assays were blinded to subject identity. Analytes of interest included biomarkers involved in Th1-and Th17-effector cell pathways associated with OSA and MS, including polarization factors [interleukins (IL)-6, IL-1, IL-12, and tissue necrosis factor (TNF)-α)], signature cytokines (IL-17 and interferon-γ), and downstream chemokines [IL-8, CXCL-1], macrophage inflammatory protein-1, and monocyte chemoattractant protein-1]. We also measured anti-inflammatory molecules IL-10 and IL-13.
NFκB signaling analysis
PBMCs collected at baseline and month 4 were analyzed for levels of proteins in the NFkB signaling pathway, namely, levels of phosphorylated Ser536 NFkB (pSer536 NFkB, a marker of NFκB activation). Cells were thawed, plated, and incubated in RPMI 1640 media supplemented with 10 per cent fetal bovine serum, 12.5 mM HEPES buffer, 1 mM sodium pyruvate, 1x nonessential amino acids, 2 mM L-glutamine, 1x Penicillin-Streptomycin, and 50 μM 2-mercaptoethanol at 37°C for 24-48 hr. Samples were then divided equally and treated with either 10 ng/mL TNF-α and 50 nM of Calyculin A, or media only for 5 min at 37°C. PBMCs were spun immediately, washed with ice cold PBS, suspended in lysis buffer (supplied with kit), and lysed by rocking at 4°C for 10 min. Total protein quantification was performed on lysates by Bradford assay. Twenty-five micrograms of total protein were used for each assay. NFκB signaling was assessed using a multiplex magnetic bead-based signaling kit (EMD Millipore, Billerica, MA) according to the manufacturer's protocol. A relative-fold change was calculated by comparing the mean fluorescent intensity (MFI) of the 4 month samples to baseline.
Statistical analyses
All statistical tests were two-sided, with a type I error rate of 0.05. Based on a power analysis of 2-sample means (group weights of 2:1), using the mean difference between baseline and 4 month respiratory disturbance index values as the primary outcome measure (δ-RDI), we estimated that n = 60 participants would provide 96 per cent power to detect a δ-RDI difference of 10 respiratory events per hour between treatment groups. Allowing for a dropout rate of 20 per cent (n = 12 participants), a sample size of 48 participants was still anticipated to yield 91 per cent power to detect an RDI difference of 10 respiratory events per hour. This level of improvement, which reflects a 50 per cent decrease in a hypothetically moderate-severity, mean baseline RDI of about 20 (consistent with a transition from moderate OSA to mild OSA, or mild OSA to no OSA) [32] , demonstrates a degree of improvement likely to be considered clinically significant.
The primary endpoint of mean change from baseline in RDI (δ-RDI) between treatment groups was first analyzed using multiple linear regression models that included the following covariates: treatment group, age, gender, change in body mass index (BMI, from baseline to month 4), change in % of total sleep time spent in REM sleep (REM%, from baseline to month 4), and change in % of total sleep time spent in supine sleep (from baseline to month 4). A mixed effects model, which treated RDI and covariates as repeated measures, treatment group as the independent variable of interest, individual ID as random effect, adjusted for age, gender, BMI, and time spent in supine sleep, was also conducted. For these models, RDI values were log-transformed prior to analyses.
For secondary endpoints, cytokine and chemokine levels were normalized by log transformation prior to examining betweengroup differences in bivariate analyses. To examine interaction effects of plasma cytokines/chemokines of interest (in separate models) on treatment effect as reflected by RDI (outcome variable), four different repeated measures models that included different levels of interaction terms were constructed. Model 1 included interaction terms between treatment and all other independent variables (age, gender, BMI, REM%, and cytokine/chemokine of interest), and interaction terms between timepoint and all independent variables. Model 2 only included an interaction term between treatment effect*cytokine/chemokine of interest, and an interaction term for timepoint*cytokine/chemokine of interest, adjusted for age, gender, BMI, and REM%. In model 3, we included the direct effects of individual cytokines on RDI only, with no interaction terms. Model 4 excluded the cytokine effect from model 3, which makes this model identical to the mixed effect RDI model in the primary analysis. Log-likelihood ratio tests were used to compare the four models for goodness of fit.
Relative fold-changes in pSer536 NFκB in TNF-α stimulated and unstimulated conditions (i.e. the quotient of stimulated/ unstimulated values) were calculated for each participant at baseline and month 4, then log-transformed for normality. Differences in log-transformed fold changes between baseline and month 4 were then compared between DMF and placebo groups using two-sample T-tests. Two-sample T-tests were also used to compare fold change differences in pSer536 NFκB between baseline and month 4 among DMF treatment responders (defined as those with an RDI reduction of 20 per cent or more on month 4 PSG) versus participants who received placebo.
Safety analyses were summarized with descriptive statistics for all patients who received at least one dose of the study drug or placebo (Common Terminology Criteria for Adverse Events, version 4.0).
Results
Baseline characteristics
Baseline characteristics are summarized in Table 1 . Among 65 randomized participants, 86 per cent of participants were white, and approximately half were female. The majority of patients had been prescribed PAP prior to enrollment. Most of those participants reported discontinuation due to intolerance. The second most commonly reported reason for PAP discontinuation was choice to pursue weight loss as a treatment modality. With the exception of N1% and supine sleep, there were no significant differences in baseline characteristics between treatment groups.
Primary analyses
A total of 65 participants were randomized: 44 to DMF and 21 to placebo. Fifty participants (DMF = 35 and placebo = 15) had complete month 4 polysomnography data for primary final analyses (Figure 1 ). The mean difference in δ-RDI between groups was 13.3 respiratory events per hour, with a mean RDI change of −3.1 events (SD = 12.9) in the DMF group and +10.2 events (SD = 13.1) in the placebo group post-treatment. Treatment effect (β = −0.14, SE = 0.06, p = 0.033) was maintained in mixed effects models, which, following log transformation of RDI, demonstrated a treatment effect of a 38 per cent decrease in RDI compared with placebo group, when controlling for baseline RDI ( In repeated measures models that examined interaction effects of cytokines/chemokines of interest, no evidence emerged for a significant interaction effect or main effect of the cytokines/chemokines on treatment effect or RDI, respectively.
Next, we compared the DMF and placebo-treated participants with respect to PBMC fold change in expression of NFκB signaling molecules, before and after stimulation with TNF-α (quotient of stimulated/unstimulated values). Differences in log-transformed fold changes in PBMC levels of pSer536 NFκB between month 4 and baseline were −0.39+/−0.67 and 0.03+/−0.79 for DMF and placebo groups, respectively (p = 0.0751). Comparisons of DMF treatment "responders" (among whom the difference in log-transformed pSer536 NFκB level fold-change values between month 4 and baseline was −0.54+/−0.66) versus placebo group showed significant differences (p = 0.0453) (Figure 2) .
Overall, DMF was well tolerated with no related serious adverse events. The most common adverse events (summarized in Table 3 ) that occurred in >=5% of at least one treatment group were flushing (DMF only), indigestion, nausea (DMF only), cold, and sinus infection (placebo only). One participant discontinued DMF at month 2 due to lymphopenia (flowchart). Flushing was the most common side effect, affecting 52 per cent of participants in the DMF group, higher than the reported 30%-40% incidence of flushing reported in previous MS trials and postmarketing data [28, 29, 33] . Four participants on DMF required a nonstandard dose (1/2 or ¾ dose) for at least a portion of the 4 month study interval due to flushing, and one additional participant discontinued DMF due to intolerable flushing (flowchart). Overall, including these individuals, mean drug adherence over the 4 month interval was excellent in the DMF group (88.7%) and in Wilcoxon Rank Sum Tests, did not differ significantly from placebo-treated participants (90.3%) (Figure 3 ).
Discussion
This phase 2 randomized, placebo-controlled trial is the first to evaluate DMF-an established immunomodulatory therapy-as a treatment for OSA, and to explore potential treatment mechanisms through modulation of inflammatory pathways. Our findings show that, in comparison to placebo, treatment with DMF partially ameliorates OSA severity among patients who are unwilling, unable, or reluctant to use PAP. The treatment effect was most readily apparent among those individuals who experienced a significant decrease in NFκB pSer536 levels (a marker of NFκB activation) over the 4 month treatment period. Although potential mechanisms for treatment effect remain speculative at this proof-of-concept stage, our findings suggest that OSA could be responsive to systemic agents that modulate immune signaling pathways. OSA and inflammation are inextricably linked. Elevated levels of proinflammatory cytokines and chemokines, including interleukins (IL)-1, IL-6, IL-8, IL-17, interferon-γ, and TNF-α, are associated with OSA [12, [34] [35] [36] [37] [38] [39] [40] [41] . They are also implicated in the development of many consequences of OSA, including cardiovascular disease, obesity, metabolic syndrome, excessive daytime sleepiness, and fatigue [11, 12, 19, [41] [42] [43] [44] . The production of these molecules is thought to be driven, in part, by NFκB [45] . It has been postulated that NFκB is activated in response to the intermittent nocturnal hypoxia that occurs in people with OSA [38] . Interestingly, however, in vivo studies in rodents suggest that systemic inflammation contributes to aberrant central ventilatory responses, possibly by modulating brainstem ventilatory control [46] . This suggests that a reinforcing loop could be perpetuated between systemic inflammation and impaired ventilation. Furthermore, although PAP is considered gold standard therapy for OSA, this treatment has not been shown to reliably reduce systemic inflammation following successful correction of the condition [15, 38, [47] [48] [49] [50] , raising the possibility that inflammation associated with OSA may not be fully explained by nocturnal hypoxia.
Recent studies of immunosuppressant therapies lend support to the concept that systemic or local inflammation could exacerbate OSA, and that such treatments could offer a highly innovative pharmacologic approach to OSA treatment. For example, compelling data from a study of obese males with OSA suggest that etanercept (Enbrel), a TNF-α antagonist used to treat rheumatoid arthritis, may improve sleep apnea severity and reduce sleepiness, while simultaneously reducing IL-6 and TNF-α levels [19] . In a separate study of spondyloarthritis patients, those who were treated with TNF-α inhibitors were found to have a lower frequency of OSA, and lower mean apnea severity than their untreated counterparts [11] . However, the side effects and risks of these immunosuppressive agents preclude their widespread use and highlight the need for studies of safer immunotherapies. Further lending support to the concept that systemic inflammation could exacerbate OSA, studies of leukotriene receptor antagonists in children [51] have demonstrated reductions in sleep apnea severity; however, these and other systemic anti-inflammatory treatments have not been sufficiently studied in adults, and causal mechanisms underlying potential treatment effects of immunomodulatory therapies on upper airway physiology are currently lacking. In contrast to immunosuppressive agents, immunomodulatory therapies such as those used to treat MS offer a safer and novel approach to the treatment of OSA, particularly for patients who are intolerant to PAP. Previous data from our group suggest a possible role for such agents. In a retrospective study, the presence of current disease modifying therapy use at time of PSG (which primarily consisted of the two most commonly used treatments during the study interval-glatiramer acetate or β-interferon) emerged as a strong and significant predictor of reduced obstructive and central sleep apnea severity [20] . The current study further supports a role for DMF, which, compared with placebo, was associated with a modest but significant reduction in OSA severity.
Although the exact mechanisms of action of the β-interferons, glatiramer acetate, and DMF have yet to be fully elucidated, convergent effects on specific proinflammatory cytokines that are both implicated in MS pathogenesis and elevated in OSA, including IL-1, IL-8, IL-6, and TNF-α, shaped our a priori hypotheses regarding potential treatment mechanisms. Down regulation of IL-1 expression has been demonstrated with all three therapies in patients with MS and murine models [22, 52, 53] . Serum levels of IL-8 (CXCL8), a chemokine that is produced in response to proinflammatory and hypoxic conditions, are reduced by β-interferon, glatiramer acetate, and DMF [21, [54] [55] [56] . In patients with MS, these medications also inhibit expression of TNF-α [22, [57] [58] [59] [60] [61] , a proinflammatory cytokine that is constitutively expressed in OSA and has been implicated in OSA pathogenesis. In our study, we observed a reduction in TNF-α-mediated NFkB signaling in PBMC following initiation of DMF, without a significant difference in plasma levels of TNF alpha. It is possible that DMF may have anti-inflammatory effects in vivo predominantly via suppression of inflammatory cell responsiveness to cytokine signaling-a future study focus. Alternatively, given the high variability of cytokine expression among and within individuals, the sample size of this phase 2 RCT may not have been sufficient to detect subtler or more complex immunological mediation effects that might well be detected with larger samples.
Fumaric acid esters such as DMF modulate multiple inflammatory pathways [62] [63] [64] [65] , chief among them, NFkB signaling [66] [67] [68] [69] . Although the exact mechanism of action is unknown, fumaric acid esters block NFkB signaling. These agents have also been shown to activate nuclear factor erythroid 2-related factor (Nrf2, a transcription factor that mediates cytoprotective responses to oxidative stress), suggesting a possible cytoprotective role [70] . In this regard, our exploratory findings regarding pSer536 NFkB levels among DMF participants deserve comment. Difference in pSer536 NFkB levels between stimulated and unstimulated conditions from baseline to month 4 (pSer536 NFkB fold change) showed a trend toward significance in comparisons between the DMF and placebo groups and were significant among DMF participants who exhibited greater reductions in RDI (i.e., those who had at least a 20% reduction at month-4 PSG). Whether this finding represents an epiphenomenon, or a causal link between DMF and apnea reduction by way of NFkB inhibition, remains uncertain but warrants further study. Some limitations must be acknowledged. Although we saw significant differences in RDI between treatment groups, we do not have a good explanation for the possible worsening of OSA severity in the placebo group during the 4 months of the study. The ever-present possibility of unanticipated changes such as this, in the absence of biological intervention, highlights the central importance of a control group. Lower baseline RDI in the placebo group could conceivably influence findings. Regression toward the mean might have predicted reduced OSA severity in both the DMF and placebo groups. Our findings may be most accurately described as amelioration of worsening in the DMF group, more than improvement from baseline. Increases in BMI over the 4 month study interval, which could explain worsening of OSA, were not seen in bivariate analyses, and treatment effect was still significant in statistical models after adjustment for BMI. We also considered the possible influence of participant dropout on baseline RDI, comparing baseline RDI among study completers with study dropouts, to determine whether dropouts had lower baseline RDI values that would drive down the baseline RDI for the entire placebo group. However, baseline RDI did not significantly differ between the dropouts and the completers (data not shown). Finally, the placebo group relative to the DMF group (Table 1) showed higher baseline stage N1% values, which by month 4 had further increased in the placebo group but decreased in the DMF group (data not shown). Stage N1 is often a marker for light, inefficient sleep. The possibility exists that a higher number of sleep-wake transitions could help to account for the higher number of scored apneic events in the placebo group at month 4. Such findings invite questions about a potential alternative mechanism of DMF impact on OSA through increased sleep consolidation, which might in itself reduce sleep-disordered breathing. Increased frequency of serological monitoring or longer treatment duration could potentially have increased our ability to detect mediation effects, if present, between inflammatory markers (such as TNF-α) and treatment effect [71] . Although a DMF dose of 240 mg BID was selected based on its efficacy in patients with MS, the possibility remains that larger treatment effects could be achieved with higher daily doses. Future dose-finding studies would be useful. Data regarding smoking status were not uniformly collected, which could also influence levels of inflammatory markers. Finally, although our immunological analysis was focused on a panel of cytokines and chemokines that have been implicated in the pathogenesis of MS and/or OSA, it was not exhaustive. Changes to other immune pathways governed by NFkB signaling but not assessed in this study also could influence OSA severity. Future experiments should expand the number of factors measured in the plasma pre-and post-initiation of DMF, and focus on the effects of immunomodulatory therapies on measures of airway mechanics, such as upper airway collapsibility.
In conclusion, our findings in previous retrospective analyses and now in this prospective, randomized trial suggest that immunomodulatory therapy-DMF in the present case-could mitigate OSA severity in patients with OSA. The degree of improvement is likely to be clinically significant, if not complete. Nonetheless, other pharmacological and nonpharmacological options currently considered for treatment of OSA when patients fail or refuse PAP similarly do not always, or completely resolve OSA [72] [73] [74] [75] . In this context of limited alternatives when it comes to treatment of OSA, the prospect of a new, well-tolerated pharmacologic approach merits additional study. A better understanding of the mechanism of action for DMF in OSA, and the immunological underpinnings of OSA, could also help us to clarify key inflammatory contributions to the etiology of a highly prevalent, consequential, and yet frequently unaddressed or incompletely controlled sleep disorder.
